Bloomios Stock Price, News & Analysis

Bloomios Inc operates as a manufacturer and distributor of hemp-derived cannabidiol (CBD) products in the United States. The company focuses on white-label and private-label manufacturing services, offering customizable product formulations for wholesale and retail distribution channels.

Through its wholly-owned subsidiary Bloomios Private Label (BPL), the company provides end-to-end manufacturing support including custom formulation development, order fulfillment, and brand development services. The subsidiary maintains capabilities across multiple product categories and manufacturing processes.

Product Portfolio and Manufacturing

The company manufactures and distributes hemp-derived products across various formats including edibles, tinctures, oils, topical salves, capsules, balms, lotions, creams, beverages, and pet treats. The product catalog encompasses over 80 distinct formulations organized across multiple product categories.

Manufacturing operations include both white-label solutions utilizing existing proprietary formulas and private-label services featuring custom formula creation. The company follows current good manufacturing practices (cGMP) and maintains compliance with occupational safety requirements in its production facilities.

The business model emphasizes providing wholesale clients with quick-to-market solutions through pre-developed formulations, while also supporting brands requiring specialized product development. Manufacturing capabilities extend to infused gummies, capsules, oils, and topical applications.

Distribution and Services

Bloomios distributes hemp-derived supplements and cosmetic products through wholesale distribution networks. The company serves retailers, e-commerce platforms, and other businesses seeking to launch CBD product lines under their own branding.

The private-label service offering includes custom formulation development, allowing clients to specify ingredient profiles, potencies, and delivery formats. White-label services provide access to established product formulations that can be branded for individual clients.

Support services encompass brand development consultation, regulatory compliance guidance, and fulfillment logistics. The company positions itself as a turnkey manufacturing partner for businesses entering the hemp-derived product market.

Industry and Market Position

The company operates within the hemp-derived supplement and cosmetic products industry. This sector experienced significant expansion following regulatory changes affecting hemp cultivation and CBD product manufacturing in the United States.

Hemp-derived CBD products are marketed for various wellness applications, though regulatory frameworks continue to evolve regarding product claims and distribution channels. The industry includes manufacturers, retailers, and service providers supporting the production and sale of cannabidiol-containing products.

Bloomios competes in the business-to-business segment of the CBD market, focusing on manufacturing services rather than direct consumer sales. The company's client base includes established brands, emerging entrepreneurs, and retail chains seeking private-label product development.

Corporate History

The entity was incorporated in 2001 under the name XLR Medical Corp. The company underwent a name change to Bloomios Inc in April 2021, reflecting a strategic repositioning toward the hemp-derived products market.

The business expanded its manufacturing capabilities through acquisitions and facility investments, including the development of specialized production infrastructure for infused products. Capacity expansions were pursued to support growing demand for white-label and private-label manufacturing services.

Operations historically centered in Santa Barbara, California, with manufacturing and distribution facilities established in Florida. The company developed partnerships with ingredient suppliers, equipment vendors, and distribution networks to support its business-to-business model.

Financial Status and Trading

The company has experienced significant financial challenges and trades on the OTC Markets at highly distressed valuations. Investors should be aware that the company announced default on senior secured notes, which triggered cross-defaults on other obligations. Secured noteholders obtained rights to potentially liquidate company assets.

The stock exhibits minimal trading volume and extremely low pricing characteristics typical of companies facing severe financial difficulties. Market capitalization reflects substantial uncertainty regarding the company's ability to continue operations or restructure its obligations.

Trading occurs on the over-the-counter market without the regulatory requirements or liquidity standards associated with major stock exchanges. The company's securities carry significant risks related to financial distress, potential asset liquidation, and uncertain business continuity.

Operational Considerations

The hemp-derived CBD industry faces ongoing regulatory scrutiny at federal and state levels. Manufacturers must navigate evolving compliance requirements regarding product testing, labeling, marketing claims, and distribution channels.

Production operations require specialized equipment for infusion processes, quality control testing, and packaging. Companies in this space typically maintain relationships with hemp cultivators, cannabinoid processors, and testing laboratories to ensure product quality and regulatory compliance.

Market dynamics for CBD products include competition from both established pharmaceutical and supplement companies, as well as smaller specialized manufacturers. Consumer demand patterns, regulatory developments, and retail acceptance all influence business prospects for companies operating in this sector.